Bones and Crohn's: Estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density

Table 1 Baseline characteristics

	Patients	Controls
Number	n = 111	n = 99
Age (yr)	35 (19 – 71)	38 (22 – 68)
Body mass index (kg/m²)	23.4 (16.8 – 34.7)	n.a.
T-score lumbar spine	-1.98 (-3.94 – 0.84)	n.a.
Patients with osteopenia (-2.5 T-score < -1)	55/49.6%	n.a.
Patients with osteoporosis (T-score < -2.5)	32/28.8%	n.a.
CDAI	104 (2 – 380)	n.a.
Duration of disease (yr)	8 (0.1 – 41.2)	n.a.
Maximal digestive extension:
- small inflammatory bowel disease	42/37.8%	n.a.
- large inflammatory bowel disease	25/22.5%	n.a.
- small and large inflammatory bowel disease	44/39.6%	n.a.
Digestive resections	54/48.7%	n.a.
Lifetime corticosteroid dose:
none	4/4.0%	n.a.
< 10 g	58/57.4%	n.a.
> 10 g	39/38.6%	n.a.
Corticosteroid users in 3 of the past 12 months	55/49.6%	n.a.
Current corticosteroid users	37/35.7%	n.a.
Current immunosuppressants (Azathioprine, 6-Mercaptopurine)	61/54.9%	n.a.
Current anti-TNF users	7/6.3%	n.a.

Data expressed as median with range shown in brackets. Qualitative data expressed as absolute values (n)/percentage.

ISSN: 1471-230X